The stock: a tale of friends and foesA lot of new investors have come into this stock story. The December volumes pre rollback attracted a lot of attention. However, most of the newbies are probably unfamiliar with why this stock was left forlorn and beaten up for for a long period of time. Simply put, a wealthy and powerful former investor/advocate wanted to wrest control of the company's IP. 91 patents and 10 years of data including large member patient clinicals is transparently worth a fortune especially on a progressive and evolving bio tech with a high efficacy rate. It was a messy battle and this post would be way too long if I elaborated on more granular details. I took the time to do considerable dd on this one and came to several conclusions:
1--this is a gift and i thank the guy that brought it to my attention.
2--the previous rogue investor and all the shenanigans has created an unparalleled buying opportunity.
3--this stock is transparently undervalued.
4--there are numerous near term catalysts: midpoint data, licensing, partnerships....
5--the IP portfolio is worth a fortune.
6--insiders are fully committed.
7--the bio-tech space is hot.
8--VC's are throwing billions into stem cell startups.
9--messaging amplification and IR campaigns will move this stock dramatically.
10--analyst coverage will validate and solidify a multi dollar price target based on peer comparables.
I see lots of upside.